Moderna announced on the 31st that it will appoint Kim Sang-pyo as the new CEO of Moderna Korea effective from the 1st of next month. Kim will succeed Son Ji-young, who has led the establishment and overall business operations of Moderna Korea since 2021, and will lead Moderna Korea going forward.
Kim said, "I am very honored to be appointed as the CEO of Moderna Korea. Korea is an important market in Moderna's global management strategy, and I feel a deep responsibility to further strengthen Moderna Korea's leadership in the field of messenger ribonucleic acid (mRNA) technology. Furthermore, I will do my best to realize Moderna's mission of unlocking the potential of mRNA medicines for humanity to the fullest extent in Korea and contribute to the promotion of public health."
Kim is regarded as an expert with over 20 years of experience and proven achievements in the pharmaceutical industry. From 2018 until recently, he served as the CEO of AstraZeneca Korea, achieving operational efficiency and growth, maximizing new product launch opportunities, and developing global business projects including the supply of COVID-19 vaccines. Previously, he held various domestic and global commercial leadership roles at MSD, including Domestic Oncology General Manager and Business Unit Director.
Patrick Bergstedt, Senior Vice President and Head of Asia and Emerging Markets at Moderna, said, "We express our deep gratitude to Son Ji-young for her dedication over the past three years and wish her the best in her future endeavors. We welcome Kim Sang-pyo as the new CEO and expect him to lead the development of Moderna Korea based on his extensive experience and profound insights in the healthcare industry."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
